Fintel reports that on June 6, 2025, Goldman Sachs initiated coverage of Teva Pharmaceutical Industries Limited - Depositary ...

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection ...

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has unveiled new data at the 2025 Psych Congress Elevate, highlighting ...

In 2020, we committed to launching eight Access to Medicines programs by 2025, aimed at providing treatments to underserved ...

Teva Pharmaceutical (TEVA) stock, Amneal Pharma (AMRX) stock receive Buy ratings and Viatris (VTRS) stock receives a Neutral rating at Goldman Sachs. Read more here.

Investing.com -- Goldman Sachs initiated coverage on U.S.-listed generic pharmaceutical companies with Buy ratings on Teva ...

Teva Pharmaceutical Industries Ltd. announced early results for its tender offers regarding multiple series of senior notes to proactively manage its debt capital structure and extend maturity ...

Teva Pharmaceutical Industries (TEVA) announced the pricing and early acceptance results of its previously announced tender offers to buy for cash the outstanding notes.

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, ...

TEVA rises 12.9% in a month as investors react to mixed first-quarter results, cost-cutting plans and growing momentum in ...

While the Trump administration’s threat of pharmaceutical import tariffs and most favored nation (MFN) drug pricing has ...